The "Europe Single-Cell Multi-Omics Market: Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The Europe single-cell multi-omics market was valued at $0.35 billion in 2023 and is expected to reach $1.71 billion by 2033, growing at a CAGR of 17.23% during the forecast period 2023-2033.
The market experiences growth due to several factors, including the increasing prevalence of large-scale genomics studies utilizing single-cell RNA sequencing (Sc-RNA), a shift towards personalized medicine using the single-cell multi-omics approach in disease screening and diagnostics, and the rising adoption of single-cell multi-omics in drug development.
Market Introduction
The Europe Single-Cell Multi-Omics Market is experiencing significant growth due to the advancements in genomics research and the increasing adoption of personalized healthcare. Researchers are leveraging single-cell multi-omics technologies to gain deeper insights into the molecular mechanisms of diseases, resulting in more precise diagnostics and treatments.
Furthermore, these technologies are revolutionizing drug development by enabling highly targeted therapeutic approaches. Europe, with its robust healthcare infrastructure and research capabilities, is at the forefront of embracing single-cell multi-omics. Collaborations among academic institutions, biotech companies, and healthcare entities are driving innovation and expanding the scope of applications for these cutting-edge technologies, contributing to the market's expansion.
How can this report add value to an organization?
Growth/Marketing Strategy: The Europe single-cell multi-omics market has seen major development by key players operating in the market, such as new offerings, partnerships, collaboration, and joint ventures.
Competitive Strategy: The Europe single-cell multi-omics market has witnessed growth in recent years; as the field of single-cell multi-omics grows, it has witnessed increased collaboration between researchers, academic institutions, and industry partners to drive innovation and commercialization of these technologies. Single-cell multi-omics technologies are already being used in various applications, such as cancer research, immunology, and neuroscience. As the technologies continue to improve, they may be applied to other areas of research, such as developmental biology and stem cell research.
Key Market Players and Competition Synopsis
- Menarini Group
- QIAGEN NV
- Rarecells Diagnostics
- Scipio Bioscience
- Singleron Biotechnologies
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 89 |
| Forecast Period | 2023 2033 |
| Estimated Market Value (USD) in 2023 | $0.35 Billion |
| Forecasted Market Value (USD) by 2033 | $1.71 Billion |
| Compound Annual Growth Rate | 17.2% |
| Regions Covered | Europe |
Key Topics Covered:
Executive Summary
Scope of the Study
Research Methodology
1 Market
1.1 Global Market Outlook
1.1.1 Product Definition
1.1.2 Inclusion and Exclusion Criteria
1.2 Market Overview
1.2.1 Key Findings
1.2.2 Current Market Scenario
1.2.2.1 For Researchers
1.2.2.2 For Diagnostics
1.3 Industry Outlook
1.3.1 Regulatory Framework
1.3.2 Patent Analysis
1.3.2.1 Awaited Technological Developments
1.3.2.2 Patent Filing Trend (by Country)
1.3.2.3 Patent Filing Trend (by Year)
1.3.3 Key Trends
1.3.3.1 Advancements in Imaging Techniques for Single-Cell Sequencing
1.3.3.2 Use of Artificial Intelligence (AI) and Machine Learning (ML) in Single-Cell Multi-Omics
1.3.3.3 Increased Development of Advanced Solution Based on Single-Cell Technology
1.3.4 Opportunity Assessment
1.3.5 Product Benchmarking
1.3.6 Clinical Trials
1.4 COVID-19 Impact
1.4.1 Pre-COVID-19
1.4.2 During COVID-19
1.4.3 Post COVID-19
1.5 Business Dynamics
1.5.1 Impact Analysis
1.5.2 Business Drivers
1.5.2.1 Rising Number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (Sc-RNA)
1.5.2.2 Use of Single-Cell Multi-Omics Approach for Screening and Diagnostics of Diseases Leading to Shift Toward Personalized Medicine
1.5.2.3 Increasing Use of Single-Cell Multi-Omics for Drug Development
1.5.2.4 Collaborations among Technology Providers and Life Sciences Companies for Accelerating the Research in Single-Cell Multi-Omics
1.5.3 Business Restraints
1.5.3.1 High Cost of Single-Cell Analysis and Sequencing
1.5.3.2 Limited Availability of Large Online Data Storage and Analysis Platforms
1.5.4 Business Opportunities
1.5.4.1 Expansion into New Research Applications, Such as Single-Cell Metabolomics
1.5.4.2 Increasing Adoption of Genomic-Based Medicine in Emerging Nations
2 Europe
2.1 Europe
2.1.1 Key Findings and Opportunity Assessment
2.1.2 Market Dynamics
2.1.2.1 Impact Analysis
2.1.3 Market Sizing and Forecast
2.1.3.1 Europe Single-Cell Multi-Omics Market (by Country)
2.1.3.1.1 Germany
2.1.3.1.2 Italy
2.1.3.1.3 U.K.
2.1.3.1.4 Spain
2.1.3.1.5 France
2.1.3.1.6 Rest-of-Europe
3 Markets Competitive Benchmarking Company Profiles
3.1 Competitive Benchmarking
3.1.1 Key Strategies and Developments
3.1.1.1 Funding Activities
3.1.1.2 New Offerings
3.1.1.3 Mergers and Acquisitions
3.1.1.4 Partnership, Collaboration, and Business Expansion
3.1.2 Market Share Analysis
3.1.3 Growth Share Analysis
3.1.3.1 By Application
3.1.3.2 By Omics Type
3.1.3.3 By Product Type
3.1.4 Visual Graphics of the Companies
3.1.5 Multi-Omics Ecosystem Active Players
3.2 Company Profiles
3.2.1 Company Overview
3.2.2 Role in the Single-Cell Multi-Omics Market
3.2.3 Analyst Perspective
For more information about this report visit https://www.researchandmarkets.com/r/71c3m9
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240213319170/en/
Contacts:
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
